57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

D. L. Gibbons; L. Q. Chow; D. W. Kim; S. W. Kim; T. Yeh; X. Song; H. Jiang; R. Taylor; J. Karakunnel; B. Creelan

doi:10.1016/S1556-0864(16)30171-X

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

D. L. Gibbons, L. Q. Chow, D. W. Kim, S. W. Kim, T. Yeh, X. Song, H. Jiang, R. Taylor, J. Karakunnel, B. Creelan

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

126 Scopus citations

Original language	English (US)
Pages (from-to)	S79
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30171-X
State	Published - Apr 2016

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/S1556-0864(16)30171-X

Cite this

Gibbons, D. L., Chow, L. Q., Kim, D. W., Kim, S. W., Yeh, T., Song, X., Jiang, H., Taylor, R., Karakunnel, J., & Creelan, B. (2016). 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. Journal of Thoracic Oncology, 11(4), S79. https://doi.org/10.1016/S1556-0864(16)30171-X

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. / Gibbons, D. L.; Chow, L. Q.; Kim, D. W. et al.
In: Journal of Thoracic Oncology, Vol. 11, No. 4, 04.2016, p. S79.

Research output: Contribution to journal › Article › peer-review

Gibbons, DL, Chow, LQ, Kim, DW, Kim, SW, Yeh, T, Song, X, Jiang, H, Taylor, R, Karakunnel, J & Creelan, B 2016, '57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC', Journal of Thoracic Oncology, vol. 11, no. 4, pp. S79. https://doi.org/10.1016/S1556-0864(16)30171-X

Gibbons DL, Chow LQ, Kim DW, Kim SW, Yeh T, Song X et al. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. Journal of Thoracic Oncology. 2016 Apr;11(4):S79. doi: 10.1016/S1556-0864(16)30171-X

@article{e2958a2d05614033b10e191328b73cc8,

title = "57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na{\"i}ve patients (pts) with EGFR mutant NSCLC",

author = "Gibbons, {D. L.} and Chow, {L. Q.} and Kim, {D. W.} and Kim, {S. W.} and T. Yeh and X. Song and H. Jiang and R. Taylor and J. Karakunnel and B. Creelan",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30171-X",

language = "English (US)",

volume = "11",

pages = "S79",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "4",

}

TY - JOUR

T1 - 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G)

T2 - A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

AU - Gibbons, D. L.

AU - Chow, L. Q.

AU - Kim, D. W.

AU - Kim, S. W.

AU - Yeh, T.

AU - Song, X.

AU - Jiang, H.

AU - Taylor, R.

AU - Karakunnel, J.

AU - Creelan, B.

PY - 2016/4

Y1 - 2016/4

UR - http://www.scopus.com/inward/record.url?scp=85043626285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043626285&partnerID=8YFLogxK

U2 - 10.1016/S1556-0864(16)30171-X

DO - 10.1016/S1556-0864(16)30171-X

M3 - Article

AN - SCOPUS:85043626285

SN - 1556-0864

VL - 11

SP - S79

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this